Skip to main content
Literatur
1.
Zurück zum Zitat Zhang J, Shao Y, Liu Y, Tao J. A multi-center, open-label, two-arm parallel group non-inferiority randomized controlled trial evaluating the effect of Pitavastatin, compared to atorvastatin, on glucose metabolism in prediabetics with hypertension and dyslipidemia: rationale and design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS). Cardiovasc Drugs Ther. 2018 Sep 5. Zhang J, Shao Y, Liu Y, Tao J. A multi-center, open-label, two-arm parallel group non-inferiority randomized controlled trial evaluating the effect of Pitavastatin, compared to atorvastatin, on glucose metabolism in prediabetics with hypertension and dyslipidemia: rationale and design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS). Cardiovasc Drugs Ther. 2018 Sep 5.
2.
Zurück zum Zitat Jonnalagadda VG, Choudhary K, Matety VK. Statins and new onset of diabetes: which one outweighs risk or benefit? Postgrad Med. 2018 Jan;130(1):146.CrossRef Jonnalagadda VG, Choudhary K, Matety VK. Statins and new onset of diabetes: which one outweighs risk or benefit? Postgrad Med. 2018 Jan;130(1):146.CrossRef
Metadaten
Titel
Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk?
verfasst von
Venu Gopal Jonnalagadda
Publikationsdatum
13.10.2018
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2019
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-018-6836-4

Weitere Artikel der Ausgabe 6/2019

Cardiovascular Drugs and Therapy 6/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.